UNLABELLED: This study assessed the radiation dosimetry of 99mTc-labeled ethylene dicysteine (EC) C225 (EC-C225), a promising radioligand for functional tumor imaging. METHODS: Whole-body scanning was performed on 6 patients with head and neck squamous cell carcinoma up to 24 h after administration of 99mTc-EC-C225. Alternate patients who had been randomized to receiveC225 in a phase III trial received 99mTc-EC-C225 before their 20-mg test dose or after their 400 mg/m2 loading dose of unlabeled C225 (patients 1/3/5 and 2/4/6, respectively). Radiation dosimetry was assessed using the MIRD method. RESULTS: The critical organ was the kidney, with an average radiation-absorbed dose for all 6 patients of 0.0274 mGy/MBq. The average total-body absorbed dose was 0.0022 mGy/MBq (0.243 cGy/1,110 MBq). CONCLUSION: The new radiopharmaceutical 99mTc-EC-C225 appears to have reasonable dosimetric properties for a diagnostic nuclear medicine agent. Correlation of the imaging results with clinical findings is the next step.
RCT Entities:
UNLABELLED: This study assessed the radiation dosimetry of 99mTc-labeled ethylene dicysteine (EC) C225 (EC-C225), a promising radioligand for functional tumor imaging. METHODS: Whole-body scanning was performed on 6 patients with head and neck squamous cell carcinoma up to 24 h after administration of 99mTc-EC-C225. Alternate patients who had been randomized to receive C225 in a phase III trial received 99mTc-EC-C225 before their 20-mg test dose or after their 400 mg/m2 loading dose of unlabeled C225 (patients 1/3/5 and 2/4/6, respectively). Radiation dosimetry was assessed using the MIRD method. RESULTS: The critical organ was the kidney, with an average radiation-absorbed dose for all 6 patients of 0.0274 mGy/MBq. The average total-body absorbed dose was 0.0022 mGy/MBq (0.243 cGy/1,110 MBq). CONCLUSION: The new radiopharmaceutical 99mTc-EC-C225 appears to have reasonable dosimetric properties for a diagnostic nuclear medicine agent. Correlation of the imaging results with clinical findings is the next step.
Authors: Diane E Milenic; Karen J Wong; Kwamena E Baidoo; Geoffrey L Ray; Kayhan Garmestani; Mark Williams; Martin W Brechbiel Journal: Cancer Biother Radiopharm Date: 2008-10 Impact factor: 3.099
Authors: Hong Song; Mohammad Hedayati; Robert F Hobbs; Chunbo Shao; Frank Bruchertseifer; Alfred Morgenstern; Theodore L Deweese; George Sgouros Journal: Mol Cancer Ther Date: 2013-07-19 Impact factor: 6.261
Authors: Tapan K Nayak; Celeste A S Regino; Karen J Wong; Diane E Milenic; Kayhan Garmestani; Kwamena E Baidoo; Lawrence P Szajek; Martin W Brechbiel Journal: Eur J Nucl Med Mol Imaging Date: 2010-02-13 Impact factor: 9.236
Authors: Karen J Wong; Kwamena E Baidoo; Tapan K Nayak; Kayhan Garmestani; Martin W Brechbiel; Diane E Milenic Journal: EJNMMI Res Date: 2011-06-07 Impact factor: 3.138
Authors: Tapan K Nayak; Kayhan Garmestani; Kwamena E Baidoo; Diane E Milenic; Martin W Brechbiel Journal: J Nucl Med Date: 2010-05-19 Impact factor: 10.057
Authors: Nikunj B Bhatt; Darpan N Pandya; Stephanie Rideout-Danner; Howard D Gage; Frank C Marini; Thaddeus J Wadas Journal: Dalton Trans Date: 2018-09-04 Impact factor: 4.390